House Pediatric Bill May Add Generic Exclusivity Provisions In Committee
Executive Summary
The House Commerce Committee is considering adding language to the pediatric exclusivity bill to cut off an effort by Bristol-Myers Squibb to block generic versions of Glucophage and BuSpar.
You may also be interested in...
Pediatric Exclusivity Advocates, House Democrats Discussing Amendments
Pediatric exclusivity advocates and House Democrats are negotiating over amendments to the Greenwood/Eshoo exclusivity reauthorization bill.
Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011